Hypoxia-Inducible Factor 1-Alpha Release After Intracoronary Versus Intramyocardial Stem Cell Therapy in Myocardial Infarction
Mariann Gyöngyösi(Medical University of Vienna), Gerald Maurer(European Society of Radiology), Noémi Pávó(Medical University of Vienna), Rayyan Hemetsberger(Medical University of Vienna), István Benedek(Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș), Imre Pávó(Eli Lilly (United States)), Silvia Charwat(Medical University of Vienna), Anikó Pósa(University of Szeged), Hani Hemetsberger(Medical University of Vienna), Imre Benedek(Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș), István Kovács(Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș), Christoph Kaun(University of Vienna), Teodora Benedek, Zsolt Petrási(University of Kaposvár), Örs Petneházy(Domus Medica)
Cited by 18
Related Papers
Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
|New England Journal of Medicine|2011|877
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
|Nature Biotechnology|2010|406
Mitochondria Are a Subset of Extracellular Vesicles Released by Activated Monocytes and Induce Type I IFN and TNF Responses in Endothelial Cells
|Circulation Research|2019|312
Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension
|Thrombosis and Haemostasis|2005|296
High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension
|Thrombosis and Haemostasis|2003|258